RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 99 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $145,476 | -94.0% | 3,543 | -93.7% | 0.00% | -100.0% |
| Q1 2024 | $2,426,870 | -16.3% | 56,009 | -11.2% | 0.00% | -33.3% |
| Q4 2023 | $2,900,017 | +129.0% | 63,085 | +14.2% | 0.00% | +50.0% |
| Q3 2023 | $1,266,446 | +43.9% | 55,243 | +3.5% | 0.00% | +100.0% |
| Q2 2023 | $879,824 | -66.6% | 53,355 | -39.1% | 0.00% | -75.0% |
| Q1 2023 | $2,637,501 | +71.3% | 87,650 | +65.7% | 0.00% | +100.0% |
| Q4 2022 | $1,539,982 | -99.9% | 52,884 | -34.7% | 0.00% | -33.3% |
| Q3 2022 | $1,982,858,000 | +2221.0% | 80,933 | +293.1% | 0.00% | – |
| Q2 2022 | $85,432,000 | -37.0% | 20,586 | +75.0% | 0.00% | – |
| Q1 2022 | $135,521,000 | -63.7% | 11,764 | -68.5% | 0.00% | -100.0% |
| Q4 2021 | $372,993,000 | +161.8% | 37,374 | +242.6% | 0.00% | – |
| Q3 2021 | $142,458,000 | +37.4% | 10,908 | +105.9% | 0.00% | – |
| Q2 2021 | $103,715,000 | -66.9% | 5,297 | -64.0% | 0.00% | – |
| Q1 2021 | $313,392,000 | +119.0% | 14,734 | +206.1% | 0.00% | – |
| Q4 2020 | $143,120,000 | -16.5% | 4,814 | -39.2% | 0.00% | – |
| Q3 2020 | $171,496,000 | +186.7% | 7,914 | +195.1% | 0.00% | – |
| Q2 2020 | $59,809,000 | -69.2% | 2,682 | -79.0% | 0.00% | – |
| Q1 2020 | $194,207,000 | +148.1% | 12,760 | +274.3% | 0.00% | – |
| Q4 2019 | $78,271,000 | +5.8% | 3,409 | -0.5% | 0.00% | – |
| Q3 2019 | $73,967,000 | +99.3% | 3,426 | +103.1% | 0.00% | – |
| Q2 2019 | $37,114,000 | -57.2% | 1,687 | -46.7% | 0.00% | – |
| Q1 2019 | $86,780,000 | +107035.8% | 3,166 | +105433.3% | 0.00% | – |
| Q4 2018 | $81,000 | -99.5% | 3 | -99.5% | 0.00% | – |
| Q3 2018 | $17,356,000 | +21.2% | 595 | +29.9% | 0.00% | – |
| Q2 2018 | $14,317,000 | -47.7% | 458 | -66.7% | 0.00% | – |
| Q1 2018 | $27,382,000 | -42.5% | 1,376 | -16.1% | 0.00% | – |
| Q4 2017 | $47,658,000 | – | 1,640 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 735,000 | $13,112,400 | 3.93% |
| NEA Management Company, LLC | 2,909,956 | $51,913,615 | 3.59% |
| Frazier Life Sciences Management, L.P. | 2,164,739 | $38,618,944 | 2.80% |
| RA Capital Management | 5,516,067 | $98,406,635 | 2.23% |
| Samsara BioCapital, LLC | 345,293 | $6,160,027 | 1.27% |
| Rock Springs Capital Management LP | 1,597,123 | $28,492,674 | 0.68% |
| Baker Brothers Advisors | 6,498,267 | $115,929,083 | 0.63% |
| HighVista Strategies LLC | 35,478 | $632,928 | 0.52% |
| Nan Fung Group Holdings Ltd | 32,520 | $580,157 | 0.40% |
| GREAT POINT PARTNERS LLC | 97,544 | $1,740,185 | 0.34% |